No Cover Image

Journal article 598 views

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Charles Lance Cowey, Christopher D Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Andrew Hill, David Hogg, Ivan Marquez-Rodas, Joel Jiang, Jasmine Rizzo, James Larkin, Jedd D Wolchok

The Lancet Oncology, Volume: 19, Issue: 11, Pages: 1480 - 1492

Swansea University Author: John Wagstaff

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1016/S1470-2045(18)30700-9

Published in: The Lancet Oncology
ISSN: 14702045
Published: 2018
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa45943
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2018-11-15T14:21:28Z
last_indexed 2019-01-28T20:00:25Z
id cronfa45943
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2019-01-28T12:47:56.3439728</datestamp><bib-version>v2</bib-version><id>45943</id><entry>2018-11-15</entry><title>Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2018-11-15</date><deptcode>SGMED</deptcode><abstract/><type>Journal Article</type><journal>The Lancet Oncology</journal><volume>19</volume><journalNumber>11</journalNumber><paginationStart>1480</paginationStart><paginationEnd>1492</paginationEnd><publisher/><issnPrint>14702045</issnPrint><keywords/><publishedDay>30</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2018</publishedYear><publishedDate>2018-11-30</publishedDate><doi>10.1016/S1470-2045(18)30700-9</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2019-01-28T12:47:56.3439728</lastEdited><Created>2018-11-15T10:50:59.0540930</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Frank Stephen</firstname><surname>Hodi</surname><order>1</order></author><author><firstname>Vanna</firstname><surname>Chiarion-Sileni</surname><order>2</order></author><author><firstname>Rene</firstname><surname>Gonzalez</surname><order>3</order></author><author><firstname>Jean-Jacques</firstname><surname>Grob</surname><order>4</order></author><author><firstname>Piotr</firstname><surname>Rutkowski</surname><order>5</order></author><author><firstname>Charles Lance</firstname><surname>Cowey</surname><order>6</order></author><author><firstname>Christopher D</firstname><surname>Lao</surname><order>7</order></author><author><firstname>Dirk</firstname><surname>Schadendorf</surname><order>8</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>9</order></author><author><firstname>Reinhard</firstname><surname>Dummer</surname><order>10</order></author><author><firstname>Pier Francesco</firstname><surname>Ferrucci</surname><order>11</order></author><author><firstname>Michael</firstname><surname>Smylie</surname><order>12</order></author><author><firstname>Andrew</firstname><surname>Hill</surname><order>13</order></author><author><firstname>David</firstname><surname>Hogg</surname><order>14</order></author><author><firstname>Ivan</firstname><surname>Marquez-Rodas</surname><order>15</order></author><author><firstname>Joel</firstname><surname>Jiang</surname><order>16</order></author><author><firstname>Jasmine</firstname><surname>Rizzo</surname><order>17</order></author><author><firstname>James</firstname><surname>Larkin</surname><order>18</order></author><author><firstname>Jedd D</firstname><surname>Wolchok</surname><order>19</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2019-01-28T12:47:56.3439728 v2 45943 2018-11-15 Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2018-11-15 SGMED Journal Article The Lancet Oncology 19 11 1480 1492 14702045 30 11 2018 2018-11-30 10.1016/S1470-2045(18)30700-9 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2019-01-28T12:47:56.3439728 2018-11-15T10:50:59.0540930 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Frank Stephen Hodi 1 Vanna Chiarion-Sileni 2 Rene Gonzalez 3 Jean-Jacques Grob 4 Piotr Rutkowski 5 Charles Lance Cowey 6 Christopher D Lao 7 Dirk Schadendorf 8 John Wagstaff 9 Reinhard Dummer 10 Pier Francesco Ferrucci 11 Michael Smylie 12 Andrew Hill 13 David Hogg 14 Ivan Marquez-Rodas 15 Joel Jiang 16 Jasmine Rizzo 17 James Larkin 18 Jedd D Wolchok 19
title Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
spellingShingle Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
John Wagstaff
title_short Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
title_full Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
title_fullStr Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
title_full_unstemmed Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
title_sort Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
author_id_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author John Wagstaff
author2 Frank Stephen Hodi
Vanna Chiarion-Sileni
Rene Gonzalez
Jean-Jacques Grob
Piotr Rutkowski
Charles Lance Cowey
Christopher D Lao
Dirk Schadendorf
John Wagstaff
Reinhard Dummer
Pier Francesco Ferrucci
Michael Smylie
Andrew Hill
David Hogg
Ivan Marquez-Rodas
Joel Jiang
Jasmine Rizzo
James Larkin
Jedd D Wolchok
format Journal article
container_title The Lancet Oncology
container_volume 19
container_issue 11
container_start_page 1480
publishDate 2018
institution Swansea University
issn 14702045
doi_str_mv 10.1016/S1470-2045(18)30700-9
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
published_date 2018-11-30T03:57:36Z
_version_ 1763752916547534848
score 11.037603

Similar Items